구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | EPCAM-targeted CAR-T cells (EPCAM-targeted CAR-T cells) Sinobioway Cell Therapy Co., Ltd.·Liver Neoplasms 1 trials |
|---|---|
Overview Program | EPCAM-targeted CAR-T cells |
Overview Company | Sinobioway Cell Therapy Co., Ltd. |
Overview Modality | CGT |
Overview Target | Liver Neoplasms |
Overview Indication | Stomach Neoplasms |
Overview Phase | PRECLINICAL |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Toxicology Major finding | Cancer Stem Cell-targeted Antibody-drug Conjugates for Cancer Immunotherapy.. Cancer stem cells (CSCs) participate in cancer initiation, metastasis, and therapy tolerance, presenting a formidable challenge in cancer treatment. Antibody-drug conjugates (ADCs) have been established as a potential strategy for selectively targeting and eradicating CSCs, thereby overcoming resistance mechanisms and pr… |
Toxicology CRS | Reported |
Clinical Safety signal | Cancer Stem Cell-targeted Antibody-drug Conjugates for Cancer Immunotherapy.. Cancer stem cells (CSCs) participate in cancer initiation, metastasis, and therapy tolerance, presenting a formidable challenge in cancer treatment. Antibody-drug conjugates (ADCs) have been established as a potential strategy for selectively targeting and eradicating CSCs, thereby overcoming resistance mechanisms and pr… |
Clinical Program phase | PRECLINICAL |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | EPCAM-targeted CAR-T cells (EPCAM-targeted CAR-T cells) Sinobioway Cell Therapy Co., Ltd.·Liver Neoplasms 1 trials |
|---|---|
Overview Program | EPCAM-targeted CAR-T cells |
Overview Company | Sinobioway Cell Therapy Co., Ltd. |
Overview Modality | CGT |
Overview Target | Liver Neoplasms |
Overview Indication | Stomach Neoplasms |
Overview Phase | PRECLINICAL |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Toxicology Major finding | Cancer Stem Cell-targeted Antibody-drug Conjugates for Cancer Immunotherapy.. Cancer stem cells (CSCs) participate in cancer initiation, metastasis, and therapy tolerance, presenting a formidable challenge in cancer treatment. Antibody-drug conjugates (ADCs) have been established as a potential strategy for selectively targeting and eradicating CSCs, thereby overcoming resistance mechanisms and pr… |
Toxicology CRS | Reported |
Clinical Safety signal | Cancer Stem Cell-targeted Antibody-drug Conjugates for Cancer Immunotherapy.. Cancer stem cells (CSCs) participate in cancer initiation, metastasis, and therapy tolerance, presenting a formidable challenge in cancer treatment. Antibody-drug conjugates (ADCs) have been established as a potential strategy for selectively targeting and eradicating CSCs, thereby overcoming resistance mechanisms and pr… |
Clinical Program phase | PRECLINICAL |
추천 비교
추천 비교